Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)

Document Details

Document Type
Pub Defense Publication
Publication Date
Aug 01, 2018
Source ID
10.1016/j.bmcl.2018.06.037

Entities

People

  • Anders Poulsen
  • Brian W. Dymock
  • Lianbin Yao
  • Pondy Murugappan Ramanujulu
  • Sten Ohlson

Organizations

  • National Health and Medical Research Council